Our Board of Directors
Tom Thambert
Board Member, Director, Nordic Capital
Tom Thambert is a member of ArisGlobal’s Board of Directors and an Investment Director at Nordic Capital, having joined the firm in March 2014. Tom focuses on investments in healthcare technology and serves on the boards of the pharma technology companies ERT and Cytel. From 2010 to 2014 he worked in the Investment Banking Division at Rothschild in London. Tom holds a BSc in Economics and Business Administration from the Stockholm School of Economics.
Fredrik Näslund
Board Member, Partner at Nordic Capital
Fredrik Näslund is a member of ArisGlobal’s Board of Directors and a Partner at Nordic Capital. He joined Nordic Capital in 2001, and has been the responsible advisor for 19 platform investments across the Technology & Payments and Healthcare sectors. Fredrik heads the Technology & Payments team. Over the last fifteen years, Fredrik has devoted significant effort in building Nordic Capital’s position as the leading private equity investor in the Technology & Payments sector, including companies like Point, Bambora, Itiviti, CINT and Trustly. Fredrik is part of Nordic Capital’s Review Committee and also Head of Norway and Denmark. Prior to joining, Fredrik was part of the management team of Capio, holding various leadership positions. Fredrik holds an MSc in Engineering Physics from the Chalmers University of Technology in Gothenburg and an MSc in Business Administration from the School of Economics and Commercial Law, University of Gothenburg.
Sankesh Abbhi
CEO, Abbhi Capital
Sankesh Abbhi is the CEO of Abbhi Capital and a member of the Board of Directors. In this role, he is focused on expanding ArisGlobal’s business by building a strong and unique platform strategy and launching important new products for the benefit of customers, patients, employees and shareholders. Sankesh has overseen back-to-back years of record growth for ArisGlobal and spearheaded the company’s relationship with Nordic Capital, delivering a long-term growth partner and opening a new chapter in ArisGlobal’s 30 year history. Sankesh began his career as the founder of Synowledge, a knowledge process outsourcing company that grew to more than 1,000 global employees and was acquired by BioClinica. In that role, he gained a unique perspective on ArisGlobal as a customer, including invaluable functional experience in drug safety, regulatory affairs, medical affairs and clinical development. Sankesh is a seasoned businessman, graduating with a BA in Economics from Columbia University.
Raj Shah
Board Member, Partner at Nordic Capital
Raj Shah is a member of ArisGlobal’s Board of Directors. He currently co-heads the Healthcare sector team at Nordic Capital and is the responsible advisor for three of Nordic Capital’s healthcare investments. Raj has over 25 years of experience in the healthcare and private equity industries. His healthcare experience spans both working as a practitioner, having initially qualified and practiced as a cardiac surgeon at Oxford, through to extensive transactional experience gained most recently as Co-Head of Goldman Sachs healthcare investment banking practice. Since 2001, Raj has advised private equity and corporate clients on over 150 transactions, including several landmark European private equity healthcare deals (including Nycomed, Gambro, Sebia and Phadia). He also holds several non-executive positions, including serving on the board of ERT, a clinical technology company, and Royal Brompton and Harefield Hospitals Charity. Raj holds a BSc and degrees in medicine and surgery, MBBS from Imperial College London, as well as being Fellow of the Royal College of Surgeons and an MBA from London Business School.
Rob Scott, MD
Chairman, ArisGlobal Advisory Board
Member, ArisGlobal Board of Directors
Dr. Rob Scott is a member of ArisGlobal’s Board of Directors and serves as the Chairman of ArisGlobal’s Advisory Board. Dr. Scott has held leadership positions for over 30 years in the world’s leading biopharma companies, including J&J, Pfizer, Amgen and AbbVie. During that time, he has led development teams responsible for highly successful brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq.
Prior to his recent retirement as Chief Medical Officer and Head of Development for AbbVie, Dr. Scott was responsible for a team of over 4,000 individuals across 52 countries, a budget of nearly US$3 billion and programs involving more than 40 new molecular entities.
Prior to joining AbbVie, Dr. Scott served as Vice President of Global Development for Amgen from 2010 to 2016, where he conducted the first outcome study for a PCSK9i, FOURIER. From 2002 until 2007, he was the Chief Medical Officer and Executive Vice President of Research and Development at AtheroGenics. While there, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. Dr. Scott also worked for Pfizer from 1992 to 2002, where he was intimately involved in many cardiovascular clinical trials.
Dr. Scott has served on many committees and boards, including as a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 until 2016, the board of Transcelerate, and as a member of the PhRMA Research and Development Leadership Forum.
Daniel Berglund
Board Member, Partner at Nordic Capital
Daniel Berglund is a member of ArisGlobal’s Board of Directors and a Partner at Nordic Capital, having joined the firm in January 2010. Daniel has served on the boards of nine Nordic Capital portfolio companies. Daniel focuses on investment situations within Technology and Payments as well has Healthcare IT. Before joining Nordic Capital, Daniel worked at Bain & CO from 2007 to 2009, most recently as a Senior Associate. Daniel holds an MSc in Economics from the Stockholm School of Economics and Business Administration from the Ross School of Business at the University of Michigan.
Michael Gordon
Chairman of the Board
With more than 18 years of experience, Mike Gordon has held several senior-level global leadership roles of increasing scope and responsibility, mainly within technology-focused organizations. Mr. Gordon’s most recent corporate leadership role was with Callcredit Information Group as Chief Executive Officer, where he oversaw a successful transformation of the business and an eventual sale to Transunion. Mr. Gordon also currently serves on the board of directors of three technology companies, Fintech, Hometrack and Constructonline.
Prior to Callcredit Information, Mr. Gordon served as FICO’s Executive Vice President of Sales, Services, and Marketing, after serving in various roles of increasing responsibility across the company’s banking, insurance, retail, health care and pharmaceutical markets. Before joining FICO in 2005, Mr. Gordon spent more than 13 years in the financial services industry. As a vice president at Capgemini (formerly Ernst & Young Consulting LLP) his competency was in providing strategic and operational solutions to banking and insurance providers, leading the Insurance Center of Excellence and Solutions.
Mr. Gordon received a BS in Industrial Engineering / Operations Research from Northwestern University and an MBA in Finance and Business Economics from The University of Chicago Graduate School of Business.